Latest / Columbus' Morning News / The hidden reason behind rising RX products
Transcript
- 0:00Speaker 1: Alright, let's go over to the Legacy Retirement Group dot
- 0:01Speaker 1: com phone line and a guest I always enjoy speaking with.
- 0:05Speaker 1: It's Antonio cha Cha, president of forty six of Brooklyn,
- 0:08Speaker 1: a prescription drug expert. Antonio, First of all, how about
- 0:12Speaker 1: your Ohio State Buckeyes beating that team up north.
- 0:15Speaker 2: Hey, I'm glad that Ryan Daig was able to shake
- 0:18Speaker 2: that monkey office back this weekend.
- 0:20Speaker 1: Absolutely absolutely, Now focusing on a Big Ten championship and
- 0:24Speaker 1: then a deep, deep playoff run resulting hopefully in back
- 0:29Speaker 1: to back national championships.
- 0:32Speaker 2: What could be better?
- 0:34Speaker 1: Not much, dude, not much.
- 0:36Speaker 2: So.
- 0:37Speaker 1: Yeah, you're somebody that tracks prescription drug coverage for Americans
- 0:41Speaker 1: and the prices of prescription drugs. And we've talked a
- 0:44Speaker 1: number of times, Antonio about the PBMs, the pharmacy benefit managers,
- 0:50Speaker 1: and those folks are really the middleman and they I
- 0:54Speaker 1: still don't know why we even have these this level
- 0:58Speaker 1: of involvement, but they're the ones who really they are
- 1:00Speaker 1: able to throttle up or throttle down prescription drug prices.
- 1:03Speaker 1: So what have drug companies done to help ease the
- 1:07Speaker 1: pain for Americans who have the high cost of prescription drugs?
- 1:12Speaker 2: Well, drug companies aren't doing very much right now, and
- 1:14Speaker 2: nobody in the drug channel is doing very much to
- 1:17Speaker 2: try and lower the costs of medicines for the end consumer.
- 1:20Speaker 2: It should be no surprise that it's in all you
- 1:24Speaker 2: can eat buffet. Anybody that can get their hands out
- 1:27Speaker 2: of plate, they will be serving themselves up some heaping
- 1:31Speaker 2: portions of drug pricing leftovers. PBMs, though structurally are supposed
- 1:38Speaker 2: to be the good guys. PBMs work on behalf of
- 1:42Speaker 2: insurance companies and health plans to try to negotiate lower
- 1:47Speaker 2: costs off of floated and inflated prices. The challenge becomes
- 1:53Speaker 2: that just like the drug companies, just like the wholesalers
- 1:57Speaker 2: and pharmacies, PBMs are also pub bookly traded companies who
- 2:01Speaker 2: want to make money off the same transactions they were
- 2:04Speaker 2: hired to control. So in some ways you can argue
- 2:08Speaker 2: they can exacerbate drug pricing dysfunction because we hire them
- 2:13Speaker 2: to control the costs of medicines, but they oftentimes end
- 2:18Speaker 2: up making matters even worse.
- 2:21Speaker 1: So did I see that some of these major insurers
- 2:24Speaker 1: like you know, United Health or Signa and in pharmacy
- 2:29Speaker 1: cb as have launched their own private label drugs.
- 2:34Speaker 2: Yes, so you know the battle the battlefield makes sense.
- 2:40Speaker 2: I think from a from a surface level, right, you
- 2:42Speaker 2: have drug companies want to charge higher prices and PBMs
- 2:47Speaker 2: are hired by our employers and our governments to try
- 2:50Speaker 2: and negotiate lower costs, and so in general you should
- 2:54Speaker 2: have a good hat fields in McCoy's relationship between the two.
- 2:59Speaker 2: But what we seen over the last few years, in
- 3:01Speaker 2: the face of growing scrutiny over PBMs driving bigger and
- 3:05Speaker 2: bigger markups on medicines. We saw this in Ohio a
- 3:08Speaker 2: few years ago with PBMs charging two hundred and forty
- 3:12Speaker 2: five million dollars in hidden spreads and fees to our
- 3:16Speaker 2: medicaid program that resulted in a national firestorm and overhaul.
- 3:20Speaker 2: Well as more and more scrutiny and reformists hit the
- 3:23Speaker 2: PBM industry, they have contorted and just when you think
- 3:27Speaker 2: you have the answers, just as Roddy Roddy Piper said
- 3:30Speaker 2: years ago, they changed the questions. And so now the
- 3:33Speaker 2: PBMs who are supposed to be fighting drug companies have
- 3:37Speaker 2: started their own drug companies, and so it really is
- 3:40Speaker 2: a great opportunity for them to kind of put their
- 3:43Speaker 2: money where their mouth is. PBMs are supposed to be
- 3:46Speaker 2: fighting high drug prices, so now that they're the drug companies,
- 3:50Speaker 2: they should be able to get them. Well. We did
- 3:52Speaker 2: a report last week where we started looking at the
- 3:57Speaker 2: prices being charged by the drug companies that are owned
- 4:01Speaker 2: by the PBMs and insurance companies, and the data was fascinating.
- 4:06Speaker 2: Of the highest priced drugs in the market, Quality Pharmaceuticals,
- 4:11Speaker 2: which is a subsidiary of Express Scripts in Signa, the
- 4:15Speaker 2: largest PBMs and insurance companies in the world, they set
- 4:20Speaker 2: prices that were just a slight discount to the highest
- 4:24Speaker 2: prices available in the market. And if you look at
- 4:27Speaker 2: the prices of their medicines, the sticker prices, and you
- 4:30Speaker 2: compare them to the lowest manufacturer prices in the market,
- 4:35Speaker 2: they were on average thirty three times higher than the
- 4:38Speaker 2: lowest prices you could find in the market.
- 4:41Speaker 1: So that doesn't seem like it makes sense. If you've
- 4:43Speaker 1: got more people the in the in the game, you
- 4:48Speaker 1: should in theoried lower prices.
- 4:52Speaker 2: Exactly. So essentially this is with looking at generic drugs.
- 4:56Speaker 2: So for those unfamiliar, when you go to the pharmacy,
- 5:00Speaker 2: there might be dozens of different options that could be
- 5:02Speaker 2: dispensed to you at the pharmacy. They all have different
- 5:06Speaker 2: sticker prices associated with them. Now, pharmacies and manufacturers can
- 5:10Speaker 2: certainly work to inflate the cost to consumers and plans,
- 5:14Speaker 2: but PBMs, again are there to be the good guys
- 5:17Speaker 2: to find the lowest prices. So one would assume if
- 5:20Speaker 2: they were actually setting the prices of the medicines that
- 5:24Speaker 2: they themselves own and distribute through their own vertically integrated company,
- 5:29Speaker 2: that they would be in the best position to get
- 5:31Speaker 2: the lowest price. But as they said, we found that
- 5:34Speaker 2: on average, of all the different interchangeable products in the marketplace,
- 5:39Speaker 2: for each drug under the Qualit brand, they were thirty
- 5:42Speaker 2: three times higher than the lowest prices in the marketplace,
- 5:46Speaker 2: which translates into higher costs for employers, government programs, and
- 5:51Speaker 2: the patients who they are supposed to be working for.
- 5:54Speaker 1: Antonia chatcha expert in drug pricing with forty six Brooklyn
- 6:00Speaker 1: concerns as to where our drugs are made, you hear
- 6:02Speaker 1: a lot about you know, we need to make more
- 6:03Speaker 1: of our drugs here domestically, a prescription drugs domestically and
- 6:07Speaker 1: and rely less on China. What's what's your take?
- 6:10Speaker 2: On that there are there's good reasons for wanting to
- 6:16Speaker 2: have a diverse portfolio of medicines that isn't solely reliant
- 6:20Speaker 2: upon foreign foreign imports. Right. China obviously is a trade
- 6:27Speaker 2: I would to say enemy, but Erica wants to put
- 6:30Speaker 2: always position itself better economically than one of its rivals
- 6:34Speaker 2: like China. As a result, when America is overly reliant
- 6:38Speaker 2: upon products that come from China, they can become bullies
- 6:42Speaker 2: if you will, when it comes to trade. So there's
- 6:45Speaker 2: been a big push by the Trump administration to try
- 6:47Speaker 2: and onshore more products. That's good for a number of reasons.
- 6:51Speaker 2: One is it can have more competition in international marketplace,
- 6:55Speaker 2: thus driving hopefully prices even lower. But it also ensures
- 6:59Speaker 2: that we don't have a concentration risk for whatever reason,
- 7:02Speaker 2: there's a natural disaster or let's say a trade war.
- 7:05Speaker 2: Anytime that we're overly reliant upon foreign born medicines, we
- 7:10Speaker 2: run a risk of essentially running out of our own supply,
- 7:13Speaker 2: which we saw a number of times during the COVID epidemic.
- 7:17Speaker 2: As there was a rush for medicines, we saw a
- 7:19Speaker 2: lot of shortages pop up internationally. So yes, we're seeing
- 7:24Speaker 2: a big focus on trying to enshore more production in
- 7:28Speaker 2: the United States so we are not as reliant upon
- 7:31Speaker 2: foreign born medicines.